-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
"Pharmaceutical network industry dynamics" a new round of national health insurance catalog adjustment has made new progress! On September 18, the State Administration of Medical Security issued an announcement on the publication of the List of Declared Medicines (hereinafter referred to as the Declaration List) for the 2020 National Health Insurance Drug Catalog Adjustment through Formal Review.
from the list of declared medicines, a total of 751 varieties have passed the formal examination, including 728 generic and Chinese medicines, and 23 Chinese medicines in the catalogue.
of these 751 varieties, there are no shortage of bright varieties.
such as Adamo mono-resistance, PD-1/PD-L1, etc.
The main function of Adamo single resistance is to regulate immune cells, was approved in the United States in 2002 and was approved for listing in China on February 26, 2010, adaptive disorders include rheumatoid arthritis, strong straight spina bifida, plaque psoriasis, Crohn's disease, early-onset idrenic arthritis and staphylococcitis.
sales of the product will reach $20.5 billion in 2018.
At present, local pharmaceutical companies have laid out Adamo single-resistant biosynthic drugs, has been listed approved companies including Baiotai, Haizheng Pharmaceuticals and Cynda Pharmaceuticals, approved three adaptive disorders including rheumatoid arthritis, strong straight spina bifida and plaque-like psoriasis.
according to Frost Sullivan, the market is expected to reach 4.7 billion yuan in 2023, with a compound annual growth rate of 291.4% from 2019 to 2023, 11.5 billion yuan in 2030 and 13.7% in 2023 to 2030.
The number of rheumatoid arthritis patients in China is increasing year by year, and according to Frost Sullivan data, the number of rheumatoid arthritis patients increased from 5.745 million to 5.878 million between 2014 and 2018, with a compound annual growth rate of 0.6%.
in the face of such a huge amount of data, with the upgrading of consumption, the domestic Adamo single resistance demand or show a rapid growth trend.
is therefore expected to gain more opportunities in the market for successful health-care access.
as far as PD-1/PD-L1 varieties are present, there are currently 8 PD-1/PD-L1 single resistances listed in China, including Roche's Atili Pearl Single Resistance, Merca East's Pablo Pearl Single Resistance, AstraZeneca The degree of Valliyu mono-resistance, hundred-time Meishi Shiguibao's Navuliyu mono-resistance, Cyntaf's Xindili mono-resistance, Junshi's Ripley mono-resistance, Baiji Shenzhou's Terelli-Pearl mono-resistance, and Hengrui Medicine's Karelli-Pearl mono-resistance.
, Thyda Bio's Xindili monoanti has entered health insurance in 2019.
this year, seven other PD-1/PD-L1 products were included in the filing list, ready for health insurance.
industry believes that Roche's Atili Pearl monoanti, AstraZeneta's Dvaliyu monoant are PD-L1 inhibitors, the current PD-L1 antibody competition is relatively moderate, therefore, there are 5 PD-1 into the first instance list.
the PD-1/PD-L1 market is promising.
the global PD-1/PD-L1 inhibitor market is expected to reach $63.9 billion by 2023, according to Frost Sullivan.
domestic level, China's PD-1/PD-L1 inhibitor market is expected to reach Rmb13.2bn in 2020, Rmb66.4bn in 2023 and Rmb98.8bn in 2030.
through lower prices into health insurance, resulting in a increase in sales of varieties.
first half of 2020 revenue was RMB920 million, an increase of 177.7% YoY, after xindili monoanti-injections from Xinda Bio were included in the health insurance policy.
industry expects that as more PD-1/PD-L1 products enter health insurance in the future, domestic PD-1 drugs account for about three-quarters of the market pattern will be maintained, and the key points of competition between manufacturers will be around the scope of adaptation, price, efficacy, time to market, health insurance qualifications and sales team number (covering the number of hospitals) and so on.